The hematology journal : the official journal of the European Haematology Association · 2003
Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Franchi-Rezgui Patricia, Rousselot Philippe, Espié Marc, Brière Josette, Pierre Marolleau Jean, Gisselbrecht Christian, Brice Pauline
Аннотация
INTRODUCTION: Owing to improved lymphoma cure rates, preserving fertility has received attention.
MATERIAL AND METHODS: Women under 40 years at diagnosis of lymphoma, treated with >/=3 chemotherapy cycles including alkylating agents and no pelvic or total body irradiation were selected. A total of 84 women fullfiled these criteria with a median age at diagnosis at 27.4 years, the duration of first-line chemotherapy ranged from 3 to 36 months (median: 7 months) and 17 women received consolidation with high-dose therapy (HDT). After complete remission, 16 women relapsed and received second-line regimen followed by HDT for 9 months.
RESULTS: With a median follow-up of 100 months, 31 women became pregnant, 34 women had primary ovarian failure (POF) and 19 women retained relative fertility. While women with preserved or relative fertility had the same clinical characteristics those with POF were older at diagnosis (30.6 versus 24.3 years), relapsed more often (34 versus 8%) and received HDT more often (54 versus 16%). After HDT (n=26), only three women (25-27 years) became pregnant.
CONCLUSION: Women given alkylating agents have a high risk of POF if they are older than 30 years at diagnosis and older than 25 years at the time of HDT. For these women with a high chance of cure and who wish to be pregnant after treatment, regimens with fewer alkylating agents should be proposed or cryopreservation of embryos when possible.
MATERIAL AND METHODS: Women under 40 years at diagnosis of lymphoma, treated with >/=3 chemotherapy cycles including alkylating agents and no pelvic or total body irradiation were selected. A total of 84 women fullfiled these criteria with a median age at diagnosis at 27.4 years, the duration of first-line chemotherapy ranged from 3 to 36 months (median: 7 months) and 17 women received consolidation with high-dose therapy (HDT). After complete remission, 16 women relapsed and received second-line regimen followed by HDT for 9 months.
RESULTS: With a median follow-up of 100 months, 31 women became pregnant, 34 women had primary ovarian failure (POF) and 19 women retained relative fertility. While women with preserved or relative fertility had the same clinical characteristics those with POF were older at diagnosis (30.6 versus 24.3 years), relapsed more often (34 versus 8%) and received HDT more often (54 versus 16%). After HDT (n=26), only three women (25-27 years) became pregnant.
CONCLUSION: Women given alkylating agents have a high risk of POF if they are older than 30 years at diagnosis and older than 25 years at the time of HDT. For these women with a high chance of cure and who wish to be pregnant after treatment, regimens with fewer alkylating agents should be proposed or cryopreservation of embryos when possible.